Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells.

Ullrich E., Bonmort M., Mignot G., Chaput N., Taieb J., Menard C., Viaud S., Tursz T., Kroemer G., Zitvogel L.
Cancer Res. 2007 Feb 1, 67 (3): 851-3.

A unique class of IFN-producing killer dendritic cells (IKDC) resembling natural killer cells has been defined that can recognize and lyse tumor cells through a tumor necrosis factor-related apoptosis-inducing ligand-dependent mechanism. IKDC may mediate the host-dependent antitumor activity of Gleevec/STI571 and other therapeutics that can inhibit the c-kit tyrosine kinase. IKDC represent an important new component of the innate immune system responding to cancer.

URL: http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?PrId=3051&itool=AbstractPlus-def&uid=17283111&db=pubmed&url=http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=17283111

Pub Med: http://www.ncbi.nlm.nih.gov/pubmed/17283111

created over 15 years ago (2 March 2009)    last modified over 13 years ago (28 September 2011)   [ RDF ]   [ RelFinder ]